ASSET PURCHASE AGREEMENT among SANOFI, VALEANT INTERNATIONAL (BARBADOS) SRL and VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Dated July 8, 2011Asset Purchase Agreement • August 8th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) is made on July 8, 2011, by and among Sanofi, a French corporation with its principal place of business located at 174, avenue de France, 75013 Paris, France (“Seller”), Valeant International (Barbados) SRL, an international society with restricted liability established under the laws of Barbados (“IP Purchaser”), and Valeant Pharmaceuticals International, Inc., a corporation organized under the laws of Canada (“Business Purchaser” and, together with IP Purchaser, “Purchasers”).
ASSET PURCHASE AGREEMENT among JANSSEN PHARMACEUTICALS, INC., VALEANT INTERNATIONAL (BARBADOS) SRL VALEANT PHARMACEUTICALS NORTH AMERICA LLC and, solely for the purposes set forth herein, VALEANT PHARMACEUTICALS INTERNATIONAL, INC. DATED AS OF JULY...Asset Purchase Agreement • August 8th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement, dated as of July 15, 2011, by and among Janssen Pharmaceuticals, Inc. a Pennsylvania corporation ("Seller"), Valeant International (Barbados) SRL, an international society with restricted liability established under the laws of Barbados ("Products Purchaser"), Valeant Pharmaceuticals North America LLC, a Delaware LLC ("Inventory Purchaser", "Employer" or, together with Products Purchaser, "Purchasers") and, solely with respect to Section 10.16, Valeant Pharmaceuticals International, Inc. ("Parent").
ContractTransition Agreement • August 8th, 2011 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • England
*** [Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. The omissions have been indicated with asterisks (“***”), and the omitted text has been filed separately with the Commission.]
